Molecular Communication-Based Intelligent Dopamine Rate Modulator for Parkinson's Disease Treatment.

Area of Science:

• Neuroscience
• Biomedical Engineering
• Molecular Communications

Background:

• Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the basal ganglia.
• Current PD treatments primarily manage symptoms and lack a definitive cure.
• Impaired neurotransmitter function in PD necessitates innovative communication-based therapeutic strategies.

Purpose of the Study:

• To introduce a novel molecular communication-based treatment for Parkinson's disease.
• To develop an Intelligent Dopamine Rate Modulator (IDRM) to address dopamine deficiency in the brain.
• To investigate the efficacy of delivering dopamine compounds to the IDRM for sustained dopamine level regulation.

Main Methods:

• A novel Intelligent Dopamine Rate Modulator (IDRM) was designed and positioned in the synaptic gap between the substantia nigra pars compacta (SNc) and striatum.
• A dopamine compound (DAC) was administered orally, traversing the digestive, circulatory, and blood-brain barrier (BBB) systems to reach the IDRM.
• Concentration calculations were performed to determine DAC uptake in various physiological regions, ensuring delivery to the IDRM.

Main Results:

• The study confirmed that the administered dopamine compound (DAC) consistently reached the Intelligent Dopamine Rate Modulator (IDRM).
• Calculated DAC concentrations indicated successful transport across the digestive system, circulatory system, and blood-brain barrier (BBB).
• The findings demonstrate the feasibility of compensating for dopamine insufficiency in the basal ganglia (BG) in Parkinson's disease (PD) models.

Conclusions:

• The Intelligent Dopamine Rate Modulator (IDRM) offers a targeted approach to compensate for dopamine deficiency in Parkinson's disease (PD).
• This molecular communication strategy minimizes off-target drug effects by localizing dopamine release.
• The method addresses the root cause of PD by restoring neurotransmitter balance, potentially offering a more effective treatment paradigm.